GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Takara Bio Inc (TSE:4974) » Definitions » Cyclically Adjusted Price-to-FCF

Takara Bio (TSE:4974) Cyclically Adjusted Price-to-FCF : 46.83 (As of Jun. 04, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Takara Bio Cyclically Adjusted Price-to-FCF?

As of today (2024-06-04), Takara Bio's current share price is 円1034.00. Takara Bio's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was 円22.08. Takara Bio's Cyclically Adjusted Price-to-FCF for today is 46.83.

The historical rank and industry rank for Takara Bio's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

TSE:4974' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 43.3   Med: 442.33   Max: 1860
Current: 46.34

During the past years, Takara Bio's highest Cyclically Adjusted Price-to-FCF was 1860.00. The lowest was 43.30. And the median was 442.33.

TSE:4974's Cyclically Adjusted Price-to-FCF is ranked better than
52.83% of 106 companies
in the Biotechnology industry
Industry Median: 49.34 vs TSE:4974: 46.34

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Takara Bio's adjusted free cash flow per share data for the three months ended in Mar. 2024 was 円5.165. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is 円22.08 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Takara Bio Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Takara Bio's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takara Bio Cyclically Adjusted Price-to-FCF Chart

Takara Bio Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 617.58 424.83 1,790.29 63.19 44.17

Takara Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.19 59.33 66.15 61.70 44.17

Competitive Comparison of Takara Bio's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Takara Bio's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takara Bio's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Takara Bio's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Takara Bio's Cyclically Adjusted Price-to-FCF falls into.



Takara Bio Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Takara Bio's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=1034.00/22.08
=46.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takara Bio's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Takara Bio's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=5.165/107.2000*107.2000
=5.165

Current CPI (Mar. 2024) = 107.2000.

Takara Bio Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 9.293 98.000 10.165
201409 -11.161 98.500 -12.147
201412 -16.227 97.900 -17.768
201503 7.026 97.900 7.693
201506 2.956 98.400 3.220
201509 -10.638 98.500 -11.578
201512 1.154 98.100 1.261
201603 11.900 97.900 13.030
201606 9.309 98.100 10.173
201609 1.088 98.000 1.190
201612 -6.453 98.400 -7.030
201703 13.221 98.100 14.447
201706 -4.169 98.500 -4.537
201709 2.026 98.800 2.198
201712 -0.930 99.400 -1.003
201803 22.530 99.200 24.347
201806 17.357 99.200 18.757
201809 2.599 99.900 2.789
201812 -13.138 99.700 -14.126
201903 -9.301 99.700 -10.001
201906 28.369 99.800 30.473
201909 -9.475 100.100 -10.147
201912 -5.439 100.500 -5.802
202003 5.539 100.300 5.920
202006 21.949 99.900 23.553
202009 -24.756 99.900 -26.565
202012 9.658 99.300 10.426
202103 35.485 99.900 38.078
202106 27.721 99.500 29.866
202109 9.808 100.100 10.504
202112 17.506 100.100 18.748
202203 -101.152 101.100 -107.255
202206 22.721 101.800 23.926
202209 22.829 103.100 23.737
202212 32.429 104.100 33.395
202303 179.586 104.400 184.402
202306 -9.060 105.200 -9.232
202309 -68.537 106.200 -69.182
202312 -20.255 106.800 -20.331
202403 5.165 107.200 5.165

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Takara Bio  (TSE:4974) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Takara Bio Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Takara Bio's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Takara Bio (TSE:4974) Business Description

Industry
Traded in Other Exchanges
Address
Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, JPN, 520-0058
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.

Takara Bio (TSE:4974) Headlines

No Headlines